TScan Therapeutics Files 10-Q, Reports Q1 2024 Results
Ticker: TCRX · Form: 10-Q · Filed: 2024-05-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotech, financing, collaboration
Related Tickers: NVS
TL;DR
TScan Q1 10-Q out: Pre-funded warrants issued April 24. Novartis collab ongoing.
AI Summary
TScan Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported its financial results and provided updates on its business operations. Key events include the issuance of pre-funded warrants on April 24, 2024, and ongoing collaborations, such as the one with Novartis initiated around March 2020.
Why It Matters
This filing provides investors with a quarterly update on TScan Therapeutics' financial health and strategic progress, including recent financing activities and ongoing partnerships.
Risk Assessment
Risk Level: medium — Biotech companies like TScan Therapeutics often carry medium risk due to the inherent uncertainties in drug development and regulatory approvals.
Key Numbers
- $0.00 — Collaboration and License Revenue (As of March 31, 2024, no revenue reported from collaborations.)
- $0.00 — Money Market Funds (As of March 31, 2024, no holdings in money market funds.)
- $0.00 — US Government Debt Securities (As of March 31, 2024, no holdings in US Government Debt Securities.)
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Filer
- Novartis (company) — Collaboration Partner
- April 24, 2024 (date) — Pre-funded Warrants Issuance Date
- March 31, 2024 (date) — Reporting Period End Date
- K2 Health Ventures (company) — Investor/Partner
FAQ
What was the total cash and cash equivalents as of March 31, 2024?
The filing does not explicitly state the total cash and cash equivalents in the provided snippet.
What is the total number of common shares outstanding as of March 31, 2024?
The filing indicates common stock and non-voting common stock outstanding as of March 31, 2024, but a specific total number is not provided in the snippet.
What are the terms of the pre-funded warrants issued on April 24, 2024?
The filing mentions the issuance of pre-funded warrants on April 24, 2024, but the specific terms are not detailed in the provided snippet.
What is the status of the collaboration with Novartis?
The filing references a collaboration with Novartis initiated around March 2020, but does not provide a current status update in the snippet.
Did TScan Therapeutics raise any additional capital through an offering in June 2023?
Yes, the filing indicates a 'Follow-on Offering' of 'Voting Common Stock' occurred on June 1, 2023.
From the Filing
0000950170-24-058198.txt : 20240513 0000950170-24-058198.hdr.sgml : 20240513 20240513073028 ACCESSION NUMBER: 0000950170-24-058198 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24936878 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 tcrx-20240331.htm 10-Q 10-Q Q1 false --12-31 0001783328 http://www.tscan.com/20240331#CollaborationAndLicenseRevenue http://www.tscan.com/20240331#CollaborationAndLicenseRevenue March 31 2020 0001783328 us-gaap:MoneyMarketFundsMember 2024-03-31 0001783328 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2024-03-31 0001783328 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001783328 tcrx:K2HealthVenturesMember 2022-09-09 2022-09-09 0001783328 tcrx:VotingCommonStockMember us-gaap:SubsequentEventMember tcrx:PreFundedWarrantsMember 2024-04-24 2024-04-24 0001783328 tcrx:PreFundedWarrantsMember 2024-03-31 0001783328 tcrx:K2HealthVenturesMember tcrx:TrancheOneMember 2022-09-09 0001783328 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001783328 tcrx:NovartisMember 2020-03-01 2020-03-31 0001783328 tcrx:FollowOnOfferingMember tcrx:VotingCommonStockMember 2023-06-01 2023-06-01 0001783328 tcrx:K2HealthVenturesMember srt:MinimumMember 2024-03-31 0001783328 2023-03-31 0001783328 us-gaap:CommonStockMember us-gaap:NonvotingCommonStockMember 2024-03-31 0001783328 tcrx:VotingCommonStockMember tcrx:PreFundedWarrantsMember 2023-06-01 0001783328 us-gaap:RetainedEarningsMember 2024-03-31 0001783328 tcrx:K2HealthVenturesMember 2024-01-01 2024-03-31 0001783328 tcrx:VotingCommonStockMember 2024-05-09 0001783328 tcrx:VotingCommonStockMember us-gaap:SubsequentEventMember tcrx:PreFundedWarrantsMember 2024-04-24 0001783328 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001783328 2024-01-01 2024-03-31 0001783328 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001783328 tcrx:VotingCommonStockMember us-gaap:CommonStockMember 2022-12-31 0001783328 us-gaap:CommonStockMember us-gaap:NonvotingCommonStockMember 2023-01-01 2023-03-31 0001783328 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-03-31 0001783328 us-gaap:CommonStockMember us-gaap:NonvotingCommonStockMember 2023-03-31 0001783328 us-gaap:RetainedEarningsMember 2023-03-31 0001783328 tcrx:VotingCommonStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001783328 2023-01-01 2023-12-31 0001783328 2023-01-01 2023-03-31 0001783328 us-gaap:NonvotingCommonStockMember 2023-12-31 0001783328 us-gaap:RetainedEarningsMember 2022-12-31 0001783328 tcrx:VotingCommonStockMember us-gaap:CommonStockMember 2023-12-31 0001783328 tcrx:VotingCommonStockMember 2024-03-31 0001783328 tcrx:VotingCommonStockMember us-gaap:CommonStockMember 2024-03-31 0001783328 tcrx:K2HealthVenturesMember srt:MaximumMember 2022-09-09 2022-09-09 0001783328 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001783328 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001783328 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001783328 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001783328 tcrx:AmgenIncMember tcrx:AmgenAgreementMember 2024-01-01 2024-03-31 0001783328 us-gaap:CommonStockMember us-gaap:NonvotingCommonStockMember 2023-12-31 0001783328 tcrx:VotingCommonStockMember tcrx:WedbushSecuritiesIncMember tcrx:SalesAgreementMember 2023-05-16 202